- Home
- PRA vs NVCR Comparison
PRA vs NVCR Comparison
Compare PRA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRA
- NVCR
- Stock Information
- Founded
- PRA 1976
- NVCR 2000
- Country
- PRA United States
- NVCR Switzerland
- Employees
- PRA N/A
- NVCR N/A
- Industry
- PRA Property-Casualty Insurers
- NVCR Medical/Dental Instruments
- Sector
- PRA Finance
- NVCR Health Care
- Exchange
- PRA Nasdaq
- NVCR Nasdaq
- Market Cap
- PRA 1.2B
- NVCR 1.4B
- IPO Year
- PRA N/A
- NVCR 2015
- Fundamental
- Price
- PRA $23.96
- NVCR $11.54
- Analyst Decision
- PRA Hold
- NVCR Buy
- Analyst Count
- PRA 4
- NVCR 7
- Target Price
- PRA $21.00
- NVCR $28.79
- AVG Volume (30 Days)
- PRA 551.0K
- NVCR 2.2M
- Earning Date
- PRA 08-05-2025
- NVCR 07-24-2025
- Dividend Yield
- PRA N/A
- NVCR N/A
- EPS Growth
- PRA N/A
- NVCR N/A
- EPS
- PRA 0.95
- NVCR N/A
- Revenue
- PRA $1,128,928,000.00
- NVCR $630,160,000.00
- Revenue This Year
- PRA N/A
- NVCR $6.15
- Revenue Next Year
- PRA $0.58
- NVCR $7.35
- P/E Ratio
- PRA $25.31
- NVCR N/A
- Revenue Growth
- PRA N/A
- NVCR 14.58
- 52 Week Low
- PRA $12.43
- NVCR $10.87
- 52 Week High
- PRA $24.14
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- PRA 65.85
- NVCR 32.75
- Support Level
- PRA $23.61
- NVCR $10.87
- Resistance Level
- PRA $24.14
- NVCR $11.99
- Average True Range (ATR)
- PRA 0.11
- NVCR 0.57
- MACD
- PRA -0.00
- NVCR 0.10
- Stochastic Oscillator
- PRA 65.09
- NVCR 25.17
About PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.